Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low Dose Long-Term Capecitabine for Refractory Field Cancerization: A Retrospective Cohort Study.

Journal of the American Academy of Dermatology·2026
Same author

A rare case of carcinoma erysipeloides/en cuirasse secondary to metastatic cutaneous apocrine adenocarcinoma.

JAAD case reports·2026
Same author

Standard neoadjuvant immunotherapy in patients with resectable stage III Melanoma - The early Australian experience.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Response to Wang et al., "Time as a Substantial Confounder in Evaluating Integrated Multidisciplinary Care for Advanced Cutaneous Squamous Cell Carcinoma".

Journal of the American Academy of Dermatology·2026
Same author

Intismeran Autogene Plus Pembrolizumab Versus Pembrolizumab Alone in High-Risk Resected Melanoma: 5-Year Update of the Randomized Phase 2b KEYNOTE-942 Study.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Surveillance Imaging in Cutaneous Squamous Cell Carcinoma: A Retrospective Analysis Informing Surveillance Recommendations.

Research square·2026
Same journal

Evolving Therapeutic Strategies in Neuroendocrine Neoplasms: A New Era of Personalized Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Multiple Chapters, One Career: Using Career Development Plans to Find Success and Satisfaction in Academic Oncology Across the Career Spectrum.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Optimal Use of Targeted Therapy and Immunotherapy in Early-Stage, Resectable Non-Small Cell Lung Cancer.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Before the Race Even Starts: Early Intervention to Prevent Long-Term Late Effects From Childhood Cancer Therapies.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Artificial Intelligence in Oncology: Practical Applications Across Clinical Care, Scholarship, and Translation.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
Same journal

Management of Bispecific Antibody Toxicities: A Focus on Multiple Myeloma.

American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting·2026
See all related articles

Related Experiment Video

Updated: Jun 27, 2026

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

Stepping Up With Immune Checkpoint Blockade: More Combinations and Fewer Contraindications.

Justine V Cohen1, Adam Adika2, Matthew Zibelman2

  • 1Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|June 25, 2026
PubMed
Summary
This summary is machine-generated.

Immune checkpoint inhibitors (ICIs) offer new cancer treatments but present challenges. This review covers ICI use in patients with autoimmune disease, complex combination regimens, and transplant recipients.

Related Experiment Videos

Last Updated: Jun 27, 2026

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

Area of Science:

  • Oncology
  • Immunology

Background:

  • Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy.
  • Expanding indications and clinical experience present complex management scenarios for oncologists.

Purpose of the Study:

  • To address critical challenges in the clinical application of immune checkpoint inhibitors.
  • To review the safe use of ICIs in patients with autoimmune diseases.
  • To discuss the toxicity profiles of novel ICI combination regimens.
  • To explore the role of ICIs in solid organ transplant recipients with cancer.

Main Methods:

  • Literature review and synthesis of current evidence.
  • Analysis of clinical trial data and expert consensus.
  • Discussion of emerging toxicities and management strategies.

Main Results:

  • Safe application of checkpoint blockade in patients with autoimmune disease is feasible with careful monitoring.
  • Combination regimens (e.g., ICI + chemotherapy, ICI + TKI, ICI + ADC) present an evolving and complex toxicity landscape.
  • Emerging evidence supports the use of ICIs in solid organ transplant recipients with advanced malignancies.

Conclusions:

  • Navigating complex scenarios in ICI therapy requires careful consideration of patient comorbidities and combination strategies.
  • Further research is needed to optimize the use of ICIs in specific patient populations and combination regimens.
  • ICI therapy continues to evolve, offering new hope for patients with advanced malignancies.